Want to see TSE:CSCI full AI Analyst Report?
CSCI Stock Chart & Stats
C$7.50
-C$0.05(-0.65%)
At close: 4:00 PM EDT
C$7.50
-C$0.05(-0.65%)
Day’s Range― - ―
52-Week RangeC$3.30 - C$14.80
Previous CloseN/A
Volume1.00
Average Volume (3M)727.00
Market Cap
C$7.60M
Enterprise ValueC$1.56
Total Cash (Recent Filing)C$5.27M
Total Debt (Recent Filing)C$1.95M
Price to Earnings (P/E)―
Beta2.70
Next Earnings
Nov 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.03
Shares Outstanding996,394
10 Day Avg. Volume647
30 Day Avg. Volume727
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.57
Price to Sales (P/S)0.29
P/FCF Ratio-0.23
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Margins And Narrowing LossesImproved gross margin and sharply lower losses indicate operating stabilization, while revenue has returned to modest growth. If production efficiencies and sales volumes persist, the business could build a better earnings base over the next several quarters.
Conservative Capital StructureManageable leverage gives COSCIENS greater financial flexibility than a highly indebted structure and reduces near-term balance-sheet pressure. This provides capacity to fund operations or development while management works toward sustainable profitability.
Structural Cost ReductionsA smaller operating cost base can improve the company’s financial runway and reduce the revenue required to approach breakeven. Suspending SEC reporting while retaining Canadian disclosure may create recurring savings, although execution remains important.
Bears Say
Persistent UnprofitabilityLosses have narrowed but remain substantial relative to revenue, showing that the business has not yet demonstrated a durable path to profitability. Continued operating losses could constrain investment, financing flexibility and shareholder returns.
Continued Cash BurnNegative operating and free cash flow means reported improvements are not yet translating into internally funded operations. Persistent cash burn may require additional financing or further cost reductions, creating dilution and execution risks over time.
Weak Continuing-operations Earnings BaseThe headline first-half profit does not represent the ongoing business alone, since discontinued operations supplied a major contribution. Continuing operations remain loss-making, making future results more dependent on core product growth and cost discipline.
COSCIENS Biopharma News
CSCI FAQ
What was COSCIENS Biopharma’s price range in the past 12 months?
COSCIENS Biopharma lowest stock price was C$3.30 and its highest was C$14.80 in the past 12 months.
What is COSCIENS Biopharma’s market cap?
COSCIENS Biopharma’s market cap is C$7.60M.
When is COSCIENS Biopharma’s upcoming earnings report date?
COSCIENS Biopharma’s upcoming earnings report date is Nov 17, 2026 which is in 70 days.
How were COSCIENS Biopharma’s earnings last quarter?
COSCIENS Biopharma released its earnings results on Aug 11, 2026. The company reported -C$0.267 earnings per share for the quarter.
Is COSCIENS Biopharma overvalued?
According to Wall Street analysts COSCIENS Biopharma’s price is currently Overvalued.
Does COSCIENS Biopharma pay dividends?
COSCIENS Biopharma does not currently pay dividends.
What is COSCIENS Biopharma’s EPS estimate?
COSCIENS Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSCIENS Biopharma have?
COSCIENS Biopharma has 996,394 shares outstanding.
What happened to COSCIENS Biopharma’s price movement after its last earnings report?
COSCIENS Biopharma reported an EPS of -C$0.267 in its last earnings report. Following the earnings report the stock price went up 3.15%.
Which hedge fund is a major shareholder of COSCIENS Biopharma?
Currently, no hedge funds are holding shares in TSE:CSCI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSCIENS Biopharma
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
Technical Analysis
BetterLife Pharma
―
PharmaTher Holdings Ltd
―
Glow LifeTech
―
Marvel Biosciences Corp
―
PharmAla Biotech Holdings, Inc.
―